Results 81 to 90 of about 6,071 (199)

GUIDELINES FOR THE USE OF SPECIFIC MONOCLONAL ANTIBODIES (PALIVIZUMAB) FOR THE PREVENTION OF RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTIONS IN SLOVENIA

Zdravniški Vestnik, 2002
Background. Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infections in children under 12 months of age. Premature children and those with chronic lung disease are at increased risk for severe RSV infection.
Marko Pokorn, Milan Čižman, Janez Primožič, Janez Babnik, Silvo Kopriva, Zdravko Roškar   +5 more
doaj  

Optimization Strategy to Minimize Wastage of Palivizumab during the 2008 RSV Season in São Paulo, Brazil

, 2009
Palivizumab is currently recommended to high-risk children as a prophylaxis for respiratory syncytial virus (RSV) infection. However, it is still very expensive for developing countries like Brazil. Herein, we describe our strategy to minimize wastage of
Moraes-Pinto, Maria Isabel de [UNIFESP], Souza, Alessandra Ramos [UNIFESP], Alves Fernandes, Marcia Monteiro [UNIFESP], Melo Pereira Monteiro, Ana Isabel [UNIFESP], Weckx, Lily Yin [UNIFESP]   +4 more
core   +1 more source

Respiratory syncytial virus-related hospitalization in premature infants without bronchopulmonary dysplasia: subgroup efficacy analysis of the IMpact-RSV trial by gestational age group

Pediatric Health, Medicine and Therapeutics, 2014
Gerard Notario,1 Pamela Vo,2 Katherine Gooch,2 Roger Deaton,3 Xionghua Wu,4 Brian Harris,4 Parthiv J Mahadevia,4 Pablo J Sánchez51Clinical Development and Medical Affairs, 2Global Heath Economics and Outcomes Research, 3Statistics, AbbVie Inc ...
Notario G, Vo P, Gooch K, Deaton R, Wu X, Harris B, Mahadevia PJ, Sánchez PJ   +7 more
doaj  

Palivizumab nella profilassi del virus respiratorio sinciziale: analisi di impatto sul budget del SSN italiano

, 2011
Palivizumab is a monoclonal antibody to RSV that has been shown to significantly reduce the frequency of hospitalisations for RSV infection, in at-risk populations. However, payers are concerned about the budgetary impact of adopting palivizumab.
Roggeri, Daniela
core   +1 more source

Palivizumab Exposure and the Risk of Atopic Dermatitis, Asthma and Allergic Rhinoconjunctivitis:A Cross-National, Population-Based Cohort Study

, 2017
Background: Palivizumab is a humanized monoclonal antibody designed to provide passive immunity against respiratory syncytial virus. It is prescribed to children at high risk for severe infection with respiratory syncytial virus. However, little is known
Marie Linder, Haerskjold, Ann, Thomsen, Simon Francis, Stensballe, Lone Graff, Berglind, Ingegärd Anveden, Henrik Ravn, Lone Graff Stensballe, Kieler, Helle, Bergman, Gunnar, Linder, Marie, Ann Haerskjold, Ravn, Henrik, Simon Francis Thomsen, Helle Kieler, Lonny Stokholm, Ingegärd Anveden Berglind, Gunnar Bergman, Stokholm, Lonny   +17 more
core   +1 more source

Evaluation of the safety of palivizumab in the second season of exposure in young children at risk for severe respiratory syncytial virus infection

, 2003
Background: Palivizumab reduces respiratory syncytial virus (RSV) hospitalisations in high-risk infants. Those with severe bronchopulmonary dysplasia may require two seasons of prophylaxis.
Wickenburg-Ennen, Barbara, Seidenberg, Juergen, Mitchell, Ian, Andre, Patrick, Nolte, Helga, Langley, Joanne J.M., Ramos, Sandra, Valido, Marques, Liska, Karel, Haumont, Dominique, Sauve, Reg R.S., Plaskie, Katleen, Lapeyre, Fabrice, Harding, Peter Andreas, Groothuis, Jessie J.R., Marques, Antónia, Kacet, Nadine, Carolino, Margarida, Cihar, Martin, Davies, Dele Dele H.D., Pollack, Paul P.F., Lequien, Pierre, Baarsma, Rienk, Allegaert, Karel, Csader, Michal, Lacaze-Masmonteil, Thierry, Cossey, Veerle, Lombet, Jacques   +27 more
core   +1 more source

DISTRIBUTION PROFILE OF PALIVIZUMAB IN BRAZIL: ANALYSIS OF REGIONAL DISTRIBUTION BETWEEN 2014 AND 2024 FOR PREVENTION OF SEVERE RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTIONS IN CHILDREN CARED FOR BY THE UNIFIED HEALTH SYSTEM (SUS)

Brazilian Journal of Infectious Diseases
Introduction/Objectives: Palivizumab is recommended to prevent severe RSV infections in children at higher risk, such as preterm infants (gestational age ≤28 weeks) and children under 2 years of age with chronic lung disease or congenital heart disease ...
Jônatas Cunha Barbosa Lima, Daniel Moreira Alves da Silva, Luciana de Vasconcelos Rebouças, Kllysmann Santos Ribeiro, Thamela Cristiny Simão Alves, Vanessa Cristina Ribeiro, Matheus Malveira Vaz, Rodrigo Ramos Sena, Nara Amanda Laismann, Ana Liani Beisl Oliveira, Rafaela Tavares Peixoto, Luiz Henrique Costa, Marco Aurelio Pereira   +12 more
doaj   +1 more source

Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants

, 2008
Asunción Mejías, Octavio RamiloDivision of Pediatric Infectious Diseases, The University of Texas Southwestern Medical Center and Children’s Medical Center, Dallas, Texas, USAAbstract: In respiratory syncytial virus (RSV ...
Octavio Ramilo, Asunción Mejías   +1 more
core  

Efficacy of Palivizumab Prophylaxis Among Infants With Congenital Heart Disease: A Case Control Study

, 2015
Background: Palivizumab prophylaxis for RSV has been consistently reported to reduce the risk of hospital admissions related to RSV infection in children with symptomatic cardiac disease. This study was designed to investigate the efficacy of palivizumab
Argun, Mustafa, Mustafa Argun, BAYKAN, Ali, Nazmi Narin, PAMUKÇU, Özge, Gokmen Zararsiz, ZARARSIZ, Gökmen, Kazim Uzum, NARİN, Nazmi, Abdullah Ozyurt, Suleyman Sunkak, Ali Baykan, SUNKAK, Süleyman, ÜZÜM, Kazım, Ozyurt, Abdullah, Ozge Pamukcu   +15 more
core   +1 more source

One-year observational study of palivizumab prophylaxis on infants at risk for respiratory syncytial virus infection in Latin America

Jornal de Pediatria
Objective: This study aims to describe real world palivizumab use and effectiveness in high-risk Latin American infants and young children. Method: Prospective, multicenter observational study with infants at risk for severe RSV infection who received ...
Leandro Martin Castillo, Gabriela Bugarin, Juan Carlos Arias, Jairo Israel Barajas Rangel, Maria Elina Serra, Nestor Vain   +5 more
doaj   +1 more source